Morningstar announces Q3 adjusted EPS of $2.55, surpassing estimates of $2.42
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 29 2025
0mins
Q3 Revenue Performance: Morningstar reported Q3 revenue of $617.4 million, exceeding estimates of $605.78 million, with strong contributions from various asset classes and platforms.
Strategic Acquisition: The planned acquisition of the Center for Research in Security Prices aims to enhance Morningstar's position as a leading index provider for US equity index funds.
New Product Launches: Morningstar introduced its first medalist ratings for semiliquid funds and launched the Morningstar PitchBook US Modern Market 100 Index.
Collaborations with AI: The company is forming new partnerships to integrate its data with prominent generative AI platforms, enhancing its service offerings.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MORN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MORN
Wall Street analysts forecast MORN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MORN is 285.00 USD with a low forecast of 250.00 USD and a high forecast of 320.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 204.600
Low
250.00
Averages
285.00
High
320.00
Current: 204.600
Low
250.00
Averages
285.00
High
320.00
About MORN
Morningstar, Inc. is a provider of independent investment insights in North America, Europe, Australia, and Asia. Its segments include Morningstar Data and Analytics, PitchBook, Morningstar Wealth, Morningstar Credit, and Morningstar Retirement. The Morningstar Data and Analytics segment provides investors comprehensive data, research and insights, and investment analysis to empower investment decision-making. The PitchBook segment provides investors with access to a broad collection of data and research covering the private capital markets. Morningstar Wealth segment brings together its model portfolios and wealth platform; practice and portfolio management software for registered investment advisers; data aggregation and enrichment capabilities; and others. Morningstar Credit segment provides investors with credit ratings, research, data, and credit analytics solutions. The Morningstar Retirement segment offers products designed to help individuals reach their retirement goals.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Berkeley Acquires Morningstar Shares: Strategic Insights
- Acquisition Overview: Berkeley acquired 17,382 shares of Morningstar in Q4 2025, valued at $3.78 million, representing 1.2% of its assets under management, indicating confidence in Morningstar's growth potential.
- Morningstar Performance: As of January 28, 2026, Morningstar's stock price was $204.66, down 38.65% over the past year, reflecting market concerns over slowing sales growth, yet Berkeley's acquisition is seen as a buy-the-dip opportunity.
- Return Analysis: Morningstar has generated an annualized return of 12.5% since 2005, outperforming the S&P 500's 11%, and its current valuation at 23 times earnings may attract long-term investors despite recent underperformance.
- Market Outlook: With a 0.9% dividend yield at its highest since 2020, Morningstar faces challenges from AI technology, leading to mixed market perceptions, but Berkeley's investment strategy reflects recognition of its long-term value.
Continue Reading
UnitedHealth Group 2025 Earnings Report Analysis
- Earnings Beat Expectations: UnitedHealth Group's Q4 2025 earnings report exceeded expectations; however, the stock plummeted 20%, indicating market disappointment with future revenue guidance, resulting in a more than 50% decline from its late 2024 peak.
- Impact of Insurance Policy: The Centers for Medicare & Medicaid Services (CMS) proposed a mere 0.09% increase in 2027 Medicare Advantage rates, significantly below the anticipated 4% to 6%, placing substantial financial pressure on UnitedHealth Group, which leads the Medicare market.
- CEO's Outlook: CEO Timothy Noel emphasized during the earnings call that the CMS proposal does not reflect the realities of medical utilization and cost trends, potentially leading to significant benefit reductions and necessitating a reevaluation of the company's geographic and product footprint.
- Long-Term Growth Potential: Despite short-term challenges, UnitedHealth Group anticipates modest growth in 2026 and a return to low double-digit earnings growth in 2027, with CEO Stephen Hemsley asserting that the company can achieve long-term growth rates of 13% to 16%, presenting potential long-term investment opportunities for shareholders.
Continue Reading